Commentary & Opinion
Kaiser Daily HIV/AIDS Report Summarizes Editorials About Tramont's Comments on HIV Vaccine Development
January 4, 2006
Two recent editorials react to comments by Edmund Tramont, director of the Division of AIDS at NIH's National Institute of Allergy and Infectious Disease, who in July 2005 during a deposition, said pharmaceutical companies likely will wait for the government to develop an effective HIV vaccine because of a lack of financial incentive to develop a vaccine in the private sector. In the deposition regarding an employment lawsuit filed by former NIH employee Jonathan Fishbein, which was obtained recently by the Associated Press, Tramont said, "[W]e're going to have an HIV vaccine," adding, "It's not going to be made by a company. They're dropping out like flies because there's no real incentive for them to do it." Therefore, he added, government agencies must spend more "time and energy" developing new treatments for market. If the government develops an effective vaccine, pharmaceutical companies will then "make it and sell it and make a profit" without having "to make that big investment," Tramont said (Kaiser Daily HIV/AIDS Report, 1/3). The editorials are summarized below.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.